UCB SA (UCB)
Euronext Brussels · Belgium · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 272.70 |
|---|---|
| 52-week range | 197.45 – 289.50 |
| Return, 1 month / 3 months | +28.9% / +12.2% |
| Return, 1 year / 3 years | +11.2% / +289.6% |
| Trend | Uptrend |
| RSI (14) | 81 |
| Volatility (1 year) | 39.3% |
| Worst drawdown (1 year) | -30.3% |
| Average daily value traded | 56.04M EUR |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UCB is a biopharmaceutical company based in Belgium that researches and develops medicines for people with severe diseases of the nervous system and immune system. Its products include treatments for epilepsy, Parkinson's disease and other neurological conditions, along with biologic therapies used in immunology and inflammatory disorders. The company serves patients and healthcare professionals through its own commercial operations in many countries and through partnerships, and it also conducts research aimed at bringing new therapies from its laboratories to clinical use.
The shares are listed on the Euronext Brussels in Belgium under the code UCB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UCB SA (UCB) trades on the Euronext Brussels in Belgium. It last closed at EUR 272.70 on 23 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 43 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.2% and over the last three months it rose 12.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 13.1% | ||
| From 52-week high | -4.5% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 12.2% | ||
| 6-month return | 11.2% | ||
| 12-month return, skipping the last month | -13.7% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 39.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.3% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 56.04M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +33.3% |
|---|---|
| 1 month | +28.9% |
| 3 months | +12.2% |
| 6 months | +11.2% |
| 1 year | +11.2% |
| 3 years | +289.6% |
| 5 years | +178.4% |
Signals
| 50-day / 200-day average | 212.81 / 241.22 |
|---|---|
| Golden / death cross (60 days) | Death, 53 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 9.34 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 May 2026 | EUR 1.0150 |
| 25 Apr 2025 | EUR 0.9730 |
| 26 Apr 2024 | EUR 0.9520 |
| 28 Apr 2023 | EUR 0.9310 |
| 29 Apr 2022 | EUR 0.9100 |
| 30 Apr 2021 | EUR 0.8890 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.